Chronic neutrophilic leukemia with dysplastic features. A new variant of the myelodysplastic syndromes

Acta Haematologica
N C ZoumbosA Kourakli-Symeonidis

Abstract

We are reporting four patients who presented with a persistent increase of mature neutrophils and band forms, no monocytosis in repeated examinations and with dysplastic features in blood and bone marrow. Two of them developed acute myeloid leukemia (AML; FAB classification M1) and the other two were characterised by a progressively aggravating myelodysplasia. All the patients showed a poor response to treatment and died within a period of time ranging from 14 to 80 months after diagnosis. We are proposing the term chronic neutrophilic leukemia with dysplastic features (CNL-D) for this entity, and we believe that it represents a variant of the myelodysplastic syndromes.

Citations

Feb 1, 1994·Annals of Hematology·R ZittounS Ramond
Sep 1, 1996·Leukemia Research·R NeuwirtováM Adamkov
May 9, 2002·Cancer Genetics and Cytogenetics·Katsuya YamamotoHiroyuki Hamaguchi
Feb 14, 2002·British Journal of Haematology·John T Reilly
Sep 1, 1992·American Journal of Hematology·T OhtsukiK Motoyoshi
Jul 29, 2015·British Journal of Haematology·Barbara J Bain, Shahzaib Ahmad
Jun 20, 2006·Best Practice & Research. Clinical Haematology·Michelle A Elliott

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.